Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 18.7% in March

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 34,300 shares, an increase of 18.7% from the March 15th total of 28,900 shares. Currently, 5.1% of the shares of the company are short sold. Based on an average daily trading volume, of 122,800 shares, the short-interest ratio is currently 0.3 days.

Institutional Trading of Aptevo Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of APVO. Sabby Management LLC purchased a new position in Aptevo Therapeutics during the third quarter valued at $440,000. Armistice Capital LLC purchased a new position in Aptevo Therapeutics during the third quarter valued at $408,000. Citadel Advisors LLC purchased a new position in Aptevo Therapeutics during the fourth quarter valued at $47,000. Cantor Fitzgerald L. P. grew its stake in Aptevo Therapeutics by 14.8% during the second quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock valued at $367,000 after acquiring an additional 32,422 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Aptevo Therapeutics by 7.3% during the first quarter. Vanguard Group Inc. now owns 240,819 shares of the biotechnology company’s stock valued at $1,414,000 after acquiring an additional 16,337 shares in the last quarter. 8.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Aptevo Therapeutics in a research note on Wednesday, April 10th. They issued a “hold” rating for the company.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ APVO traded down $0.06 during midday trading on Monday, reaching $0.78. The stock had a trading volume of 465,918 shares, compared to its average volume of 204,535. The stock has a 50-day moving average of $5.15 and a 200-day moving average of $8.05. Aptevo Therapeutics has a 12-month low of $0.76 and a 12-month high of $91.96.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.